
Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.
Over the course of the first five weeks, more than 8,000 prescriptions have been issued for the new obesity drug, which is based around the GLP-1 analog semaglutide. This is a significantly faster development than what Novo Nordisk's other drug Saxenda went through, which was launched in 2015. It is based on the substance liraglutide, which is a predecessor to semaglutide.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app